Lir Therapeutics
Lir Therapeutics develops engineered viral vectors to improve the safety, efficacy, and cost profile of gene therapies. The company focuses on redesigning adeno-associated virus (AAV) capsids using an AI-first platform that combines lab-in-the-loop active learning and therapeutically relevant model design to modify whole viruses. Lir operates as a biotech R&D organization targeting other biotech and gene therapy developers, applying machine learning, protein engineering, and experimental screens. Their technology stack centers on AI, AAV engineering, and gene therapy discovery workflows. The company addresses large unmet needs in gene delivery by enabling next-generation vectors for clinical and commercial use.
Lir Therapeutics
Lir Therapeutics develops engineered viral vectors to improve the safety, efficacy, and cost profile of gene therapies. The company focuses on redesigning adeno-associated virus (AAV) capsids using an AI-first platform that combines lab-in-the-loop active learning and therapeutically relevant model design to modify whole viruses. Lir operates as a biotech R&D organization targeting other biotech and gene therapy developers, applying machine learning, protein engineering, and experimental screens. Their technology stack centers on AI, AAV engineering, and gene therapy discovery workflows. The company addresses large unmet needs in gene delivery by enabling next-generation vectors for clinical and commercial use.